Literature DB >> 22497996

The N-terminal region of the human 5-HT₂C receptor has as a cleavable signal peptide.

Jan Anker Jahnsen1, Staffan Uhlén.   

Abstract

The 5-hydroxytryptamine 2C (5-HT(2C)) receptor has a single nucleotide polymorphism (SNP) site at amino acid position 23 in its N-terminal tail. The polymorphism involves conversion of a cysteine to serine. The site, designated C23S, is located within a 32 amino acid long predicted signal peptide. The aim of the present study was to investigate whether the 5-HT(2C) receptor indeed has a functional cleavable signal peptide. For this purpose, ten N-terminally modified 5-HT(2C) receptors were constructed. Modifications included addition of the influenza virus hemagglutinin signal peptide, addition of a FLAG epitope, truncation of the N-terminal tail, and combinations of these changes. The receptors were transiently expressed in COS-7 cells. The relative amounts of receptors expressed at the membranes were quantified by [(3)H]-mesulergine radioligand binding. In one of the receptor constructs the FLAG epitope was inserted just after the endogenous putative signal peptide. Immunostaining with the M1 antibody, which recognizes the FLAG epitope only as free N-terminal entity, was used to detect whether the putative signal peptide preceding the FLAG epitope was cleaved off. The results suggest the following conclusions. The predicted signal peptide in the N-terminal tail of the 5-HT(2C) receptor acts as a cleavable signal peptide. Cleaving of the signal peptide is important for translocation of the wild type receptor to the plasma membrane. The two amino acids differentially encoded by the C23S SNP are likely absent from the mature 5-HT(2C) receptor.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22497996     DOI: 10.1016/j.ejphar.2012.03.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  The C-terminal half of the α2C-adrenoceptor determines the receptor's membrane expression level and drug selectivity.

Authors:  Jan Anker Jahnsen; Staffan Uhlén
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-20       Impact factor: 3.000

2.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

3.  Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders.

Authors:  Valentina A Toshchakova; Yalda Bakhtiari; Alexander V Kulikov; Sergey I Gusev; Marina V Trofimova; Olga Yu Fedorenko; Ekaterina V Mikhalitskaya; Nina K Popova; Nikolay A Bokhan; Johannes E Hovens; Anton J M Loonen; Bob Wilffert; Svetlana A Ivanova
Journal:  Neuropsychobiology       Date:  2018-04-05       Impact factor: 2.328

4.  A putatively functional polymorphism in the HTR2C gene is associated with depressive symptoms in white females reporting significant life stress.

Authors:  Beverly H Brummett; Michael A Babyak; Redford B Williams; Kathleen Mullan Harris; Rong Jiang; William E Kraus; Abanish Singh; Paul T Costa; Anastasia Georgiades; Ilene C Siegler
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

5.  Serotonin 5-HT2C Receptor Cys23Ser Single Nucleotide Polymorphism Associates with Receptor Function and Localization In Vitro.

Authors:  Michelle A Land; Holly L Chapman; Brionna D Davis-Reyes; Daniel E Felsing; John A Allen; F Gerard Moeller; Lisa A Elferink; Kathryn A Cunningham; Noelle C Anastasio
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

6.  The Serotonin Receptor Subtype 5b Specifically Interacts with Serotonin Receptor Subtype 1A.

Authors:  Sabine Niebert; Gijsbert J van Belle; Steffen Vogelgesang; Till Manzke; Marcus Niebert
Journal:  Front Mol Neurosci       Date:  2017-09-21       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.